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Background: We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval
provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
Methods: Patients X18 years received oral sunitinib 50mg per day on a 4-weeks-on–2-weeks-off schedule. Safety was assessed
regularly. Tumour measurements were scheduled per local practice.
Results: A total of 4543 patients received sunitinib. Median treatment duration and follow-up were 7.5 and 13.6 months. Objective
response rate was 16% (95% confidence interval (CI): 15–17). Median progression-free survival (PFS) and overall survival (OS) were
9.4 months (95% CI: 8.8–10.0) and 18.7 months (95% CI: 17.5–19.5). Median PFS in subgroups of interest: aged X65 years (33%),
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10.1 months; Eastern Cooperative Oncology Group performance status X2 (14%), 3.5 months; non-clear cell histology (12%), 6.0
months; and brain metastases (7%), 5.3 months. OS was strongly associated with the International Metastatic Renal-Cell Carcinoma
Database Consortium prognostic model (n¼ 4065). The most common grade 3/4 treatment-related adverse events were
thrombocytopenia (10%), fatigue (9%), and asthenia, neutropenia, and hand–foot syndrome (each 7%).
Conclusion: Final analysis of the sunitinib expanded-access trial provided a good opportunity to evaluate the long-term side
effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.
Sunitinib is an orally administered multitargeted inhibitor of
vascular endothelial growth factor receptors (VEGFRs), platelet-
derived growth factor receptors, and other receptor tyrosine
kinases (Abrams et al, 2003; Mendel et al, 2003; O’Farrell et al,
2003). The efficacy of sunitinib demonstrated in two phase II trials
of patients with cytokine-refractory advanced renal cell carcinoma
(RCC) led to its conditional approval (Motzer et al, 2006a,b). In a
subsequent pivotal phase III registration trial of treatment-naive
patients with metastatic RCC (mRCC), sunitinib demonstrated a
significant improvement in progression-free survival (PFS)
compared with interferon-alfa (median PFS 11 vs 5 months;
hazard ratio (HR): 0.42, Po0.001) and in objective response rate
(ORR; 31% vs 6%, Po0.001; Motzer et al, 2007); in addition,
overall survival (OS) was longer with sunitinib (median 26.4 vs
21.8 months; HR: 0.821, P¼ 0.051; Motzer et al, 2009). Given the
lack of active agents available in 2005 to treat advanced RCC, a
global, expanded-access trial was implemented to provide sunitinib
to patients in countries where its approval had not yet been granted
and to those ineligible for registration-directed trials. Initial results
from this expanded-access programme confirmed the activity of
sunitinib in a broader ‘real-world’ population (Gore et al, 2009).
Here we report final results with extended follow-up of the 4543
patients treated in the expanded-access trial. This extensive
database was also used in an exploratory analysis to provide
further external validation of the RCC prognostic model from the
International Metastatic Renal-Cell Carcinoma Database Consor-
tium (IMDC; Heng et al, 2009, 2013).
PATIENTS AND METHODS
Patients. All patients were aged 18 years or older with
histologically confirmed mRCC that was either treatment-naive
or previously treated. Other requirements were as follows:
resolution of prior treatment toxicities, adequate organ function,
no major comorbidities, the potential to derive clinical benefit from
sunitinib as judged by the treating physician, and ineligibility for
other sunitinib studies. Any Eastern Cooperative Oncology Group
(ECOG) performance status and asymptomatic brain metastases
were permitted. Full details for eligibility criteria have been
previously reported (Gore et al, 2009). All patients gave written,
informed consent.
Study design and treatment. This was an international, open-
label, expanded-access trial of sunitinib (SUTENT; Pfizer Inc., New
York, NY, USA) that treated patients from participating centres in
50 countries. The primary objective of the study was to provide
sunitinib to patients with mRCC and no access to the drug who
might benefit from treatment. Secondary objectives included
assessment of efficacy and toxicity in the overall population, as
well as in subgroups of interest.
The first patient was enrolled in June 2005. Accrual discon-
tinued on a country-by-country basis according to treatment
availability, with the last patient enrolled in December 2007. All
patients received oral sunitinib at a starting dose of 50mg per day
for 4 weeks on treatment followed by 2 weeks off treatment in
repeated 6-week cycles (schedule 4/2). Provision was made for dose
reduction to 37.5mg per day and if needed to 25mg per day on the
basis of individual tolerance. A protocol amendment in May
2006 provided investigators with the option of administering
sunitinib on a continuous daily dosing schedule (usual starting
dose 37.5mg per day). Treatment continued until disease
progression, unacceptable toxicity, or withdrawal of consent. The
study was approved by the institutional review board or
independent ethics committee at each participating centre, and
was run in accordance with the International Conference on
Harmonization Good Clinical Practice Guidelines.
Study assessments. Screening evaluations included disease assess-
ment, physical examination, biochemistry and haematology tests, and
a record of concomitant medications. Monitoring safety was
mandatory at regular intervals (on days 1, 14, and 28 of cycle 1,
and days 1 and 28 of subsequent cycles, until a protocol amendment
(May 2006) removed the day 28 assessment in cyclesX3) by physical
examination, ECOG performance status, haematology and bio-
chemistry tests and cardiac function (12-lead electrocardiogram), and
by recording and grading all adverse events (AEs) according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events (Cancer Therapy Evaluation Program, 2006).
No specific schedule was dictated by the protocol; however,
tumour measurement was assessed by Response Evaluation
Criteria in Solid Tumors (RECIST), version 1.0 (Therasse et al,
2000). Assessments were performed as per the local standard of
care for mRCC, with data on tumour response, PFS, and OS
collected when possible. Objective response rate was defined as the
number of confirmed complete plus partial responses according to
RECIST (Therasse et al, 2000). Progression-free survival was
defined as the time from start of therapy to disease progression or
death from any cause (whichever occurred first). Only deaths that
occurred within 28 days of the last dose were counted as PFS
events; however, disease progression was not restricted to the
treatment period plus the 28-day follow-up period. OS was defined
as the time from start of therapy to death from any cause. Patients
who were not known to be dead at the time of analysis or on the
data cutoff date (September 2008) were censored on the date that
they were last known to be alive.
Statistical analysis. Because of the nature of this study, there was
no pre-determined sample size nor were inferential analyses
preplanned or any pre-specified hypotheses tested. All patients
who received at least one dose of sunitinib were included in the
current analyses (modified intention-to-treat population), except
for patients with non-RECIST tumour measurements (n¼ 324),
who were excluded from efficacy analyses based on tumour
response data. Objective response rate was calculated with
corresponding exact 95% two-sided confidence interval (CI) using
standard methods based on the binomial distribution. The Kaplan–
Meier method was used to estimate PFS and OS, with 95% CI
calculated for the median.
In an exploratory analysis, patients were grouped into favour-
able (0 adverse factors), intermediate (1–2 adverse factors), and
poor (X3 adverse factors) risk categories according to the IMDC
model (Heng et al, 2009, 2013), with median OS for each group
estimated by the Kaplan–Meier method and compared by the log-
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rank test. Adverse factors were ECOG performance status 41,
time from diagnosis to study treatment o1 year (calculated as the
time from original diagnosis to the date of the first sunitinib dose
in the current study), haemoglobino lower limit of normal (LLN),
calcium4 upper limit of normal (ULN), neutrophil count4ULN,
and platelet count4ULN. In addition, a Cox multivariate analysis
was used to explore the association between OS and the IMDC
prognostic factors. All P-values were considered exploratory.
RESULTS
Patients. In total, 4577 patients were enrolled into the study,
including 4543 patients who received at least one dose of sunitinib
and comprised the population for analysis purposes. Baseline
patient characteristics are described in Table 1. The broad trial
population included patient subgroups of interest, including
patients age X65 years (33%) and those with ECOG performance
status X2 (14%), non-clear cell RCC (12%), and brain metastases
(7%). Overall, 26% of patients were classified as having a poor
prognosis (Table 1), according to modified risk groups based on
published Memorial Sloan-Kettering Cancer Center (MSKCC)
criteria (Motzer et al, 2002, 2004).
Treatment exposure. Patients received a median of six cycles
(range: 1–57), with median treatment duration of 7.5 months (95%
CI: 6.9–7.8). Median follow-up (the time from the start of therapy
until the patient was censored for survival or died, whichever
occurred first) was 13.6 months (range:o1–71.3 months), and was
similar for those who previously had or had not received cytokine
therapy. At the time of analysis, 4298 patients (95%) had
discontinued treatment. Among these patients, the most common
reasons for stopping therapy were lack of efficacy (39%), death
(21%), AE (16%), consent withdrawn (9%), and lost to follow-up
(3%). Overall, 49% of patients required a dose reduction of
sunitinib. The dose was reduced to 37.5mg per day in 34% of
patients, to 25mg per day in 15% of patients, and to 12.5mg per
day in o1% of patients. (Seventy patients (2%) were assigned to
and received 37.5mg per day on a continuous daily dosing
schedule.) Dose reductions of sunitinib occurred at a higher
frequency in patients who received prior cytokine treatment for
advanced RCC, compared with those who had not received
cytokines (51% vs 47%).
Safety. Approximately 95% of patients reported treatment-related
AEs of any grade, the most frequent of which were diarrhoea
(47%), fatigue (40%), nausea (36%), and decreased appetite
(31%; Table 2). All-grade hypothyroidism was reported as a
treatment-related AE in 11% of patients, and proteinuria was
reported in 1% of patients overall. (Routine testing of thyroid
function was not required; however, urinalysis (dipstick protein
urinalysis) to monitor proteinuria was done at screening, day 1 of
cycle 2, as clinically indicated, and at the end of treatment.) The
most commonly reported treatment-related grade 3/4 AEs
included thrombocytopenia (10%), fatigue (9%), asthenia, hand–
foot syndrome, and neutropenia (each 7%), hypertension (6%),
and diarrhoea (5%; Table 2). In this large population, the reported
overall incidence of cardiac disorders considered treatment related
was 6% (grade 3/4o2%). Rates of all-grade cardiac failure or
congestive cardiac failure were o1%. Twelve patients (o1%) died
as a result of a treatment-related cardiac event, including cardiac
failure (n¼ 4), myocardial infarction (n¼ 5), and cardiac arrest,
cardiopulmonary failure, and myocarditis (each n¼ 1).
Sixty-eight patients (1%) died from other treatment-related
(non-cardiac) AEs, the most frequent of which were cerebral
haemorrhage (n¼ 6), death (n¼ 5), hepatic and renal failure
(each n¼ 4), and gastrointestinal haemorrhage, general physical
health deterioration, pulmonary embolism, respiratory failure, and
septic shock (each n¼ 3). Among the more commonly reported
AEs, two patients died as a result of thrombocytopenia and
asthenia (each n¼ 1), as reported by the investigators.
Serum chemistry laboratory tests showed a transient increase in
median alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST), alkaline phosphatase (ALP), and lactate dehydrogenase
levels during cycles 1–3 that stabilised at values near or below
baseline in subsequent cycles (data not shown). Clinically
significant elevations in ALT or AST were each reported as all-
grade treatment-related AEs in 3% of patients, with similar
incidences of both and ALP reported as all-grade AEs of any cause
(Supplementary Table 1).
The incidences of non-haematological, sunitinib-related AEs of
any grade in subgroups of interest were comparable to (for patients
aged X65 years; Supplementary Table 2; and those with RCC of
non-clear histology (data not shown)) or apparently lower than
Table 1. Baseline patient characteristics
Characteristic Sunitinib (N¼4543)
Median age (range), years 59.0 (19.0–89.0)
Age X65 years, n (%) 1485 (33)
Male/female, n (%) 3364/1179 (74/26)
ECOG performance status, n (%)a
0 1868 (41)
1 1949 (43)
2 547 (12)
3 80 (2)
4 7 (o1)
Histology, n (%)a
Clear cell 4010 (88)
Non-clear cell 532 (12)
Prior nephrectomy, n (%)a 4044 (89)
Disease sites, n (%)
Lung 3469 (76)
Lymph nodes 2333 (51)
Bone 1593 (35)
Liver 1236 (27)
Brain 338 (7)
Prior systemic therapy, n (%)
Antiangiogenicb 440 (10)
Cytokine 3096 (68)
Modified risk groups based on published MSKCC data, n (%)a,c
Favourable 915 (20)
Intermediate 1495 (33)
Poor 1177 (26)
Risk groups based on the IMDC prognostic model, n (%)a,d
Favourable 988 (22)
Intermediate 2188 (48)
Poor 889 (20)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; IMDC¼ International Meta-
static Renal-Cell Carcinoma Database Consortium; LLN¼ lower limit of normal; MSKCC¼
Memorial Sloan-Kettering Cancer Center; ULN¼upper limit of normal.
aNumber (%) of patients with missing data: ECOG performance status¼ 92 (2), histology¼ 1
(o1), prior nephrectomy ¼ 199 (4), modified risk groups based on published MSKCC data
(Motzer et al, 2002, 2004)¼ 956 (21), risk groups based on the IMDC prognostic model
(Heng et al, 2009, 2013)¼ 478 (11).
bIncluded sorafenib and bevacizumab.
cRisk factors were ECOG performance statusX2, haemoglobinoLLN, and corrected serum
calcium 410mgdl 1; patients without prior cytokine treatment also had lactose
dehydrogenase 41.5ULN and time to interferon-alfa use of o1 year as risk factors
(Motzer et al, 2002, 2004). Patients with prior cytokine therapy were assigned to favourable,
intermediate, or poor risk groups if 0, 1, or 41 risk factors were present, respectively.
Patients without prior cytokine treatment were assigned to favourable, intermediate, or
poor risk groups if 0, 1 or 2, or 42 risk factors were present, respectively.
dRisk factors were ECOG performance status 41, time from diagnosis to study treatment
o1 year, haemoglobinoLLN, calcium4ULN, neutrophil count 4ULN, and platelet count
4 ULN (Heng et al, 2009, 2013). Patients with 0, 1 or 2, or 42 risk factors were assigned to
the favourable, intermediate, or poor risk groups, respectively.
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(for those with brain metastases (data not shown), and ECOG
performance statusX2; Supplementary Table 3) that in the overall
population. The overall incidence of non-haematological grade 3/4
AEs was broadly similar across the subgroups and when compared
with the overall population, with the exception of the elderly
subgroup (X65 years), in which the total incidence appeared
slightly higher (61%) than in patients o65 years of age (51%).
Otherwise, the incidences of the most commonly reported non-
haematological AEs were generally similar in both age groups
(Supplementary Table 2).
Of interest, the overall incidence of grade 3/4 AEs appeared to
be slightly lower in patients with ECOG performance status X2
(46%) than in patients with ECOG performance status 0 or 1
(56%). Otherwise, the incidences of the most commonly reported
grade 3/4 AEs were generally similar, with more apparent variation
in the incidences of grade 1/2 AEs according to performance status
(Supplementary Table 3).
The safety profile of sunitinib appeared generally unchanged
with long-term follow-up. When the final data reported here were
compared with interim results reported in 2009 (Gore et al, 2009),
the frequency and grade of common AEs were similar, except for a
numerical increase in all-grade hypothyroidism (11% vs 6%).
Efficacy. A total of 4219 mRCC patients were included in the
analysis of tumour response, of whom 63 patients achieved a
complete response (1%) and 597 patients a partial response
(14%), yielding an ORR of 16% (95% CI: 15–17; Table 3). The
ORR was similar in patients with and without previous cytokine
treatment, and also similar in elderly patients (X65 years)
compared with younger patients (o65 years; Table 3). Responses
were reported among patients in all subpopulations of interest
(Table 3). Patients at favourable risk based on the modified
MSKCC prognostic criteria fared better than those at poor risk,
with ORRs of 26%, 16%, and 9% in the favourable, intermediate,
and poor risk groups, respectively (as originally classified before
the exploratory analysis using the IMDC model). Approximately
45% of patients in the overall population had stable disease for at
least 3 months, with similar rates regardless of prior cytokine
treatment, among elderly patients, and in those with RCC of non-
clear cell histology; patients with ECOG performance status X2
or brain metastases were less likely to achieve durable stable
disease (Table 3). Progressive disease or stable disease o3
months was found in 19% of patients.
Within the limits of the lack of strictly standardised criteria for
the timing and methodology of assessment of disease status, in the
evaluable population, median PFS was 9.4 months (95% CI: 8.8–
10.0) and median OS was 18.7 months (95% CI: 17.5–19.5;
Figure 1 and Table 4). More than 20% of patients were still alive at
5 years. Median survival times were unaffected by prior cytokine
status and were also similar in elderly patients compared with
younger patients; however, it may have been affected by inclusion
of patients with brain metastases or non-clear cell RCC (Table 4).
In patients with either RCC of non-clear cell histology, brain
metastases, or ECOG performance status X2, both PFS and OS
were substantially shorter than in the overall population (Table 4).
PFS and OS also varied in patients classified according to the
modified MSKCC prognostic criteria. In the favourable, inter-
mediate, and poor risk groups, respectively, median PFS was 15.0
months (95% CI: 13.8–16.3), 10.6 months (95% CI: 9.4–11.1), and
5.4 months (95% CI: 5.1–5.7), while median OS was 56.5 months
(95% CI: 41.6 to not reached), 20.0 months (95% CI: 18.4–21.3),
and 9.1 months (95% CI: 8.4–9.7). The efficacy of sunitinib was
maintained with long-term follow-up and was not markedly
different, when final data were compared with interim results
reported in 2009 (Gore et al, 2009; data not shown).
IMDC prognostic model. Data on the IMDC prognostic risk
factors were available for a total of 4065 patients. In a multivariate
Cox analysis of OS, all six factors (ECOG performance status 41,
time from diagnosis to treatment o1 year, haemoglobin o LLN,
calcium 4 ULN, neutrophil count 4 ULN, and platelet count 4
ULN) were significantly associated with reduced OS (each
Po0.001; Table 5). OS was significantly different between patient
subpopulations classified as having poor (n¼ 889; median 6.2
months), intermediate (n¼ 2188; median 18.9 months), and
favourable risk (n¼ 988; median 45.4 months), according to the
IMDC model (Figure 2; for favourable vs intermediate or poor
subgroups: HR: 0.3593, Po0.001; for poor vs favourable or
intermediate subgroups: HR: 3.5153, Po0.001). Therefore, despite
the inclusion of patients with brain metastases and non-clear cell
RCC, this large sunitinib database validated external data for
prognostic criteria according to the IMDC factors.
DISCUSSION
The final analysis of this global, expanded-access trial of sunitinib
in advanced mRCC confirms the efficacy and safety of this agent in
44500 patients in a real-world setting. Although the results
presented here are limited by the nature of the expanded-access
Table 2. Treatment-related adverse events of interest and
those that occurred in X10% of the modified intent-to-treat
population (N¼4543)
Adverse event
Grade 1/2,
n (%)
Grade 3/4,
n (%)
Total, N
(%)a
Non-haematologic
Diarrhoea 1885 (41) 237 (5) 2122 (47)
Fatigue 1406 (31) 403 (9) 1809 (40)
Nausea 1517 (33) 111 (2) 1629 (36)b
Decreased appetite 1295 (29) 102 (2) 1398 (31)b
Mucosal inflammation 1195 (26) 137 (3) 1332 (29)
Stomatitis 1144 (25) 133 (3) 1277 (28)
Vomiting 1107 (24) 143 (3) 1250 (28)
Hand–foot syndrome 909 (20) 311 (7) 1221 (27)b
Dysgeusia 1124 (25) 28 (1) 1152 (25)
Hypertension 837 (18) 267 (6) 1104 (24)
Asthenia 713 (16) 306 (7) 1021 (22)b,c
Dyspepsia 828 (18) 16 (o1) 844 (19)
Rash 734 (16) 38 (1) 772 (17)
Constipation 628 (14) 12 (o1) 641 (14)b
Epistaxis 585 (13) 31 (1) 616 (14)
Yellow skin 588 (13) 5 (o1) 593 (13)
Headache 495 (11) 26 (1) 521 (11)
Hypothyroidism 489 (11) 27 (1) 516 (11)
Skin discolouration 487 (11) 4 (o1) 491 (11)
Hair colour changes 481 (11) 9 (o1) 490 (11)
Dry skin 458 (10) 3 (o1) 461 (10)
Pain in extremity 413 (9) 42 (1) 455 (10)
ALT increased 94 (2) 23 (1) 117 (3)
Cardiac failure 0 13 (o1) 17 (o1)
Congestive cardiac failure 1 (o1) 13 (o1) 14 (o1)
Haematologicd
Thrombocytopenia 741 (16) 440 (10) 1182 (26)
Neutropenia 486 (11) 315 (7) 801 (18)
Anaemia 594 (13) 203 (4) 798 (18)b
Leukopenia 414 (9) 97 (2) 511 (11)
Abbreviation: ALT¼ alanine aminotransferase.
aEighty patients (2%) died from treatment-related adverse events (data not shown, except
for cardiac failure (n¼ 4) and asthenia and thrombocytopenia (both n¼ 1)).
bGrade missing for one patient.
cIncludes one patient with grade 5 asthenia, a 55-year-old female with a medical history of
hypertension and Hodgkin’s disease, who had baseline Eastern Cooperative Oncology
Group performance status of 2, and massive liver metastases, and pulmonary and
mediastinal metastases before the start of the study; in addition to asthenia, other
treatment-related serious adverse events experienced by the patient included dyspnoea,
thrombopenia, hypotension, and hypothermia.
dRelated haematological adverse events with different preferred terms were collected and
pooled.
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study design, these findings are particularly valuable due to the
large patient population. Combined with the extended duration of
patient follow-up, this provides a good opportunity to evaluate
sunitinib toxicity and long-term side effects. The sunitinib safety
profile described here was consistent with the approved labelling
for sunitinib (SUTENT (sunitinib malate) prescribing information)
and provides an update to the preliminary findings from
the interim report of data from this trial (Gore et al, 2009),
with the exception of an apparent increase in the frequency of
hypothyroidism (11% vs 6%) reported as an AE, potentially due to
an increased awareness of this AE over time. The incidence of
many commonly reported AEs also increased slightly, which is not
unexpected given the increased treatment exposure (6 vs 5 cycles,
respectively) and longer median follow-up (13.6 vs 11.6 months,
respectively) in this final analysis. Low rates of all-grade,
treatment-related cardiac events (6%) were observed. Efficacy
outcomes were consistent with previously published findings from
registration-directed phase II and III clinical trials (Motzer et al,
2006a, b, 2007, 2009). In those studies, the ORR was higher at
30–40%, compared with 16% here, in which tumour assessments
were done as per the local standard of care for RCC. However,
median PFS was 11 months in the first-line setting and 8.3 and
8.7 months in the cytokine-refractory setting, compared with
9.4 months here. OS was 26.4 months and 16.4 months in the first-
line and cytokine-refractory settings, respectively, compared with
our finding of 18.7 months. Notably, 420% of patients in the
current study survived for 5 years or longer. In addition to
subgroups of interest included in the expanded-access trial
(notably patients with ECOG performance status X2 or brain
metastases), 68% of patients had received prior cytokine therapy
and 10% had been previously treated with antiangiogenic agents.
All of these factors might be expected to negatively impact on PFS
and OS in the overall study population. In this context, however, it
is worth emphasising that efficacy was in fact comparable in
patients regardless of prior cytokine treatment.
The efficacy of sunitinib in patients with brain metastases, poor
performance status, and non-clear cell RCC compares favourably
with historical data for these subgroups. The safety profile of
sunitinib in these three subgroups was similar to that overall,
although the incidence of treatment-related AEs was consistently
lower in the poor performance status and brain metastases
subgroups. This may be due to shorter drug exposure; for example,
patients with brain metastases received a median three cycles
(range: 1–50), compared with six cycles (range: 1–57) in the overall
population. Safety and efficacy in the fourth subgroup analysed,
comprising elderly patients aged X65 years, were broadly similar
to that observed in younger patients (o65 years). This is an
important finding, as this age group encompasses 64% of newly
diagnosed RCC cases and accounts for 422% of deaths from this
disease (Howlader et al, 2012). The observed activity of sunitinib in
the elderly has been confirmed in an extensive retrospective
analysis of data pooled from 1059 patients in six clinical trials of
sunitinib as first-line or cytokine-refractory treatment for advanced
RCC, which found no difference in efficacy between patients aged
Table 3. Tumour response according to RECIST (version 1.0) and clinical benefit
Prior cytokine
treatment
Patient subgroups
All patientsa
(N¼4219)
Yes
(n¼2907)
No
(n¼1312)
Age X65
years
(n¼1386)
Age o65
years
(n¼2833)
ECOG PS
X2 (n¼587)
Non-clear cell
histology
(n¼505)
Brain
metastases
(n¼324)
Number of evaluable patients 3353 2343 1010 1030 2323 300 379 215
Objective response, n (%) 660 (16) 444 (15) 216 (16) 195 (14) 465 (16) 32 (5) 42 (8) 30 (9)
Complete response, n (%) 63 (1) 34 (1) 29 (2) 8 (1) 55 (2) 1 (o1) 4 (1) 3 (1)
Partial response, n (%) 597 (14) 410 (14) 187 (14) 187 (13) 410 (14) 31 (5) 38 (8) 27 (8)
Stable disease X3 months, n (%) 1893 (45) 1347 (46) 546 (42) 596 (43) 1297 (46) 149 (25) 217 (43) 107 (33)
Progressive disease or stable
disease o3 months, n (%)
800 (19) 552 (19) 248 (19) 239 (17) 561 (20) 119 (20) 120 (24) 78 (24)
Clinical benefit,b n (%) 2553 (61) 1791 (62) 762 (58) 791 (57) 1762 (62) 181 (31) 259 (51) 137 (42)
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group performance status; RECIST¼Response Evaluation Criteria in Solid Tumors.
aOverall, 324 patients were excluded from the modified intent-to-treat population for objective response due to non-RECIST tumour assessments. A further 866 patients were included in the
analysis but were not assessed (n¼ 250), not evaluable (n¼ 19), or had missing data (n¼ 597).
bClinical benefit¼objective responseþ stable disease for X3 months.
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Figure 1. Kaplan–Meier estimates of (A) PFSa and (B) OS for the
overall population. aIn the PFS plot, 324 modified intent-to-treat
patients were excluded from the evaluable population due to non-
RECIST tumour assessment.
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X70 years and o70 years (Hutson et al, 2014). In the same
analysis, although most treatment-emergent AEs occurred at
similar rates in each age group, some were significantly more
common in older vs younger patients, including fatigue, cough,
peripheral oedema, anaemia, decreased appetite, and thrombo-
cytopenia (all Po0.05). Despite these observations, advanced age
alone is not a reason to withhold sunitinib treatment for advanced
RCC, as older patients derive a similar efficacy benefit as younger
ones.
Antitumour activity has also been observed in patients who
received sunitinib with a primary tumour in place. In an interim
analysis of data from this study, the safety profile of sunitinib was
similar in patients with a prior nephrectomy and those without a
prior nephrectomy (Szczylik et al, 2008). However, efficacy
outcomes were more favourable in patients with a prior nephrectomy
than in those without (e.g. median PFS, 12.0 vs 6.5 months,
respectively; P¼ 0.0021), thereby indirectly supporting the value of
cytoreductive nephrectomy in the era of targeted agents, as also
recently reported elsewhere (Aizer et al, 2014; Heng et al, 2014).
In an exploratory analysis, we found a strong association
between OS and the IMDC prognostic factors (Heng et al,
2009, 2013), validating this model in 44000 patients receiving
treatment in the tyrosine kinase inhibitor era. (In the original Heng
et al. (2009), median OS was not reached in the favourable risk
Table 4. Summary of median progression-free survival and overall survival
Prior cytokine treatment Patient subgroups
All patients
(N¼4543)
Yes
(n¼3096)
No
(n¼1447)
Age
X65 years
(n¼1485)
Age
o65 years
(n¼3058)
ECOG
PS X2
(n¼634)
Non-clear cell
histology
(n¼532)
Brain
metastases
(n¼338)
Included in PFS
analysis,a n
4219 2907 1312 1386 2833 587 505 324
Median PFS
(95% CI), months
9.4 (8.8–10.0) 9.3 (8.6–10.1) 9.7 (8.4–10.8) 10.1 (8.8–10.9) 9.2 (8.5–9.8) 3.5 (2.8–4.2) 6.0 (5.4–7.0) 5.3 (4.4–5.6)
Median OS
(95% CI), months
18.7 (17.5–19.5) 18.4 (17.1–19.5) 19.0 (17.2–21.0) 18.1 (16.5–20.3) 18.8 (17.4–19.8) 5.7 (4.9–6.4) 12.2 (10.2–14.2) 8.2 (7.4–9.6)
Abbreviations: CI¼ confidence interval; ECOG PS¼Eastern Cooperative Oncology Group performance status; OS¼overall survival; PFS¼progression-free survival; RECIST¼Response
Evaluation Criteria in Solid Tumors.
aOverall, 324 patients were excluded from the modified intent-to-treat population for PFS analysis because of non-RECIST tumour assessment. Survival events including all deaths were
collected up to September 2008.
Table 5. Multivariate Cox analysis of overall survival using the IMDC prognostic factors
Parameter Parameter estimate±s.e. Hazard ratio 95% CI P-value
ECOG PS 41 0.79±0.05 2.20 1.98–2.44 o0.0001
Time from diagnosis to treatment o1 year 0.28±0.04 1.32 1.21–1.44 o0.0001
Haemoglobin o LLN 0.61±0.05 1.84 1.68–2.01 o0.0001
Calcium4ULN 0.34±0.06 1.41 1.25–1.59 o0.0001
Neutrophil count 4 ULN 0.71±0.05 2.03 1.83–2.25 o0.0001
Platelet count 4 ULN 0.31±0.05 1.36 1.23–1.50 o0.0001
Abbreviations: CI¼ confidence interval; ECOG PS¼Eastern Cooperative Oncology Group performance status; IMDC¼ International Metastatic Renal-Cell Carcinoma Database Consortium;
LLN¼ lower limit of normal; s.e.¼ standard error; ULN¼ upper limit of normal.
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Figure 2. Kaplan–Meier estimates of OS for the overall population, according to prognostic risk group based on the IMDC model (Heng et al,
2009, 2013). N¼4065.a aIn total, 478 patients were excluded due to missing data for one or more risk factors.
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group; however, the 2-year OS rate was 75%, which is similar to the
results in this study.) Numerous prognostic models for RCC have
been developed over the past decades, in parallel with new
treatment options for this disease. To our knowledge, the data
reported here represent the largest contemporary patient popula-
tion evaluated to date using an RCC prognostic model. That said,
given the nature of our study, the characteristics of these patients,
especially those in the intermediate and poor risk groups, may not
be entirely equivalent to those of patients in the original Heng et al.
(or MSKCC) model (Motzer et al, 2002; Heng et al, 2009).
The landscape for managing advanced RCC is rapidly changing,
with a range of targeted agents now approved for the treatment of
this disease. Despite limitations such as lack of a comparator and
lack of independent review of tumour response, expanded-access
trials are a practical way of offering a particular treatment to
registration-directed, trial-ineligible patients and of gathering data
about its activity in a real-world setting of very diverse patients. To
date, the sunitinib expanded-access trial is the largest reported of
its kind globally in the mRCC population. Two expanded-access
trials have also been conducted with sorafenib in patients with
advanced RCC, one based in the United States (n¼ 2504) and one
in Europe (n¼ 1150; Stadler et al, 2010; Beck et al, 2011). The
European trial limited patients to those in whom at least one
previous line of systemic therapy had failed, or who were unable to
tolerate cytokine therapy, whereas the US trial included treatment-
naive patients. In each case, the safety and efficacy of sorafenib was
consistent with that reported for the pivotal phase III trial
(Escudier et al, 2007), and activity was seen in subgroups of interest
similar to those included in the sunitinib expanded-access trial.
Likewise, no new safety issues were identified in an international
expanded-access programme of everolimus in a restricted popula-
tion of patients with mRCC after failure of initial VEGFR-directed
therapy (n¼ 1367) (Gru¨nwald et al, 2012). In this trial, median
treatment duration was only 14 weeks, which may reflect the
treatment setting, but which also means that safety and efficacy
data gathered were limited in comparison with the sunitinib trial.
This expanded-access trial in mRCC has considerably extended
our knowledge of the efficacy and safety of sunitinib in a real-world
setting, and enabled over 4500 patients with wide-ranging disease
states to receive sunitinib treatment. The sunitinib safety profile
was consistent with prior reports, no unexpected long-term AEs
were reported, and clinical benefit was seen in both treatment-
naive and previously treated patients, in older as well as younger
patients, and in those with traditionally poor prognosis.
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